Summary
The company
LenioBio is a biotech company that develops and markets a novel, unique and proprietary protein production platform, ALiCE®, which enables protein-based therapeutics to become more accessible and affordable and specifically targeting the substantial but underserved class of ‘difficult-to-express (DTE) proteins’.
LenioBio has developed a proprietary tobacco-based cell-free protein synthesis (CFPS) platform “ALiCE” with a higher yield (3 mg/ml) than any other eukaryotic cell-free system currently available (0.2 mg/ml) at a lower cost, while ensuring protein stability and activity.
The goal of PEPPER is to bring LenioBio to a position of competitiveness and growth to be able to meet the current industrial demands of ‘difficult- to-produce’ proteins for various biotechnology sectors (e.g. pharmaceutical, and agricultural industries). To achieve this, LenioBio will scale-up the protein production capacity and yield to be able to produce proteins at an industrial scale using a semi- automated platform, while complying to GMP protocols and FDA/EMA regulations for biopharmaceuticals proteins.
LenioBio’s mission is to offer a fully integrated protein production platform for pharmaceutical and biotechnology companies with the ability to scale along with our customers’ needs. LenioBio is developing the ALiCE® technology into the first eukaryotic cell-free production platform for any proteins.
LenioBio launched its first product as a protein expression kit in 2018 under the name ALiCE® (Almost Living Cell-free Expression). Due to its sustainable competitive advantages, already within nine months, 8 of the top 10 biopharma companies are customers, with more in the process of registering LenioBio as a vendor.
LenioBio is a biotech company that develops and markets a novel, unique and proprietary protein production platform, ALiCE®, which enables protein-based therapeutics to become more accessible and affordable and specifically targeting the substantial but underserved class of ‘difficult-to-express (DTE) proteins’.
LenioBio has developed a proprietary tobacco-based cell-free protein synthesis (CFPS) platform “ALiCE” with a higher yield (3 mg/ml) than any other eukaryotic cell-free system currently available (0.2 mg/ml) at a lower cost, while ensuring protein stability and activity.
The goal of PEPPER is to bring LenioBio to a position of competitiveness and growth to be able to meet the current industrial demands of ‘difficult- to-produce’ proteins for various biotechnology sectors (e.g. pharmaceutical, and agricultural industries). To achieve this, LenioBio will scale-up the protein production capacity and yield to be able to produce proteins at an industrial scale using a semi- automated platform, while complying to GMP protocols and FDA/EMA regulations for biopharmaceuticals proteins.
LenioBio’s mission is to offer a fully integrated protein production platform for pharmaceutical and biotechnology companies with the ability to scale along with our customers’ needs. LenioBio is developing the ALiCE® technology into the first eukaryotic cell-free production platform for any proteins.
LenioBio launched its first product as a protein expression kit in 2018 under the name ALiCE® (Almost Living Cell-free Expression). Due to its sustainable competitive advantages, already within nine months, 8 of the top 10 biopharma companies are customers, with more in the process of registering LenioBio as a vendor.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: | https://cordis.europa.eu/project/id/881025 |
Start date: | 01-12-2019 |
End date: | 28-02-2022 |
Total budget - Public funding: | 3 391 250,00 Euro - 2 373 875,00 Euro |
Cordis data
Original description
The companyLenioBio is a biotech company that develops and markets a novel, unique and proprietary protein production platform, ALiCE®, which enables protein-based therapeutics to become more accessible and affordable and specifically targeting the substantial but underserved class of ‘difficult-to-express (DTE) proteins’.
LenioBio has developed a proprietary tobacco-based cell-free protein synthesis (CFPS) platform “ALiCE” with a higher yield (3 mg/ml) than any other eukaryotic cell-free system currently available (0.2 mg/ml) at a lower cost, while ensuring protein stability and activity.
The goal of PEPPER is to bring LenioBio to a position of competitiveness and growth to be able to meet the current industrial demands of ‘difficult- to-produce’ proteins for various biotechnology sectors (e.g. pharmaceutical, and agricultural industries). To achieve this, LenioBio will scale-up the protein production capacity and yield to be able to produce proteins at an industrial scale using a semi- automated platform, while complying to GMP protocols and FDA/EMA regulations for biopharmaceuticals proteins.
LenioBio’s mission is to offer a fully integrated protein production platform for pharmaceutical and biotechnology companies with the ability to scale along with our customers’ needs. LenioBio is developing the ALiCE® technology into the first eukaryotic cell-free production platform for any proteins.
LenioBio launched its first product as a protein expression kit in 2018 under the name ALiCE® (Almost Living Cell-free Expression). Due to its sustainable competitive advantages, already within nine months, 8 of the top 10 biopharma companies are customers, with more in the process of registering LenioBio as a vendor.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all